Sam Klempner, medical-oncologist, Massachusetts General Hospital and Harvard Medical School, Boston, USA

Biography

Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI esophagogastric task force, and is on the NCCN guideline committees for gastric and esophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and esophageal cancer outreach and patient advocacy.

Summary of presentation

In this presentation we will cover the biologic rationale and clinical support for Claudin18.2-directed therapies in gastroesophageal cancers.